Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
RESOLUTE
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
2 other identifiers
interventional
689
29 countries
338
Brief Summary
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 chronic-obstructive-pulmonary-disease
Started Aug 2019
Longer than P75 for phase_3 chronic-obstructive-pulmonary-disease
338 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 16, 2019
CompletedFirst Posted
Study publicly available on registry
August 12, 2019
CompletedStudy Start
First participant enrolled
August 26, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 28, 2025
CompletedAugust 19, 2025
August 1, 2025
5.9 years
July 16, 2019
August 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Annualized rate of moderate or severe COPD exacerbations
Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD
Over first 56 weeks
Secondary Outcomes (16)
Annualized rate of severe COPD exacerbations
Minimum of 1 year and an average of 2 years
Annualized rate of COPD exacerbations that are associated with an emergency room/emergency department visit or a hospitalization
Minimum of 1 year and an average of 2 years
Time to first COPD exacerbation
During first 56 weeks
Change from baseline in SGRQ total and domain scores
up to 56 weeks
Change from baseline in E-RS:COPD total and domain scores
up to 56 weeks
- +11 more secondary outcomes
Other Outcomes (1)
Safety and tolerability of benralizumab in patients with moderate to very severe COPD
Minimum of 1 year and average of 2 years
Study Arms (2)
Benralizumab
EXPERIMENTALAdministrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
Placebo
PLACEBO COMPARATORAdministrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
Interventions
Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Eligibility Criteria
You may qualify if:
- Provision of informed consent
- Age 40 to 85 years
- Male and/or female.
- Current or former smoker with a tobacco history of ≥10 pack-years.
- History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC\<0.70 and FEV1 ≤65% of predicted normal value.
- Documented history of 2 or more COPD exacerbations that required treatment with systemic corticosteroids and/or hospitalization within 52 weeks prior to enrollment.
- Exacerbations treated with antibiotics alone are excluded unless accompanied by treatment with systemic corticosteroids and/or hospitalization.
- Hospitalization is defined as an inpatient admission ≥24 hours
- Previous exacerbations should be confirmed to have occurred while on stable triple therapy for COPD.
- At least one qualifying COPD exacerbation should occur while on stable uninterrupted triple therapy prior to enrolment.
- Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for ≥3 months immediately prior to enrollment.
- Treatment with at least double inhaled therapy containing ICS (e.g. ICS/LABA or ICS/LAMA) for the remaining of 52 weeks prior to enrolment. Use of LABA/LAMA is allowed if ICS cannot be tolerated.
- ICS in a dose approved for COPD or equivalent to ≥250 mcg of fluticasone propionate daily.
- Total cumulative duration of not being on double or triple background therapy must not exceed 2 months.
- Stable therapy/doses for the last 3 months prior to randomization.
- +5 more criteria
You may not qualify if:
- Clinically important pulmonary disease other than COPD
- Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
- Radiological findings of a respiratory disease other than COPD contributing to respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or findings of acute infection.
- Another pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
- Any unstable disorder that could affect patient safety, study findings or the patient's ability to complete the study.
- Any clinically significant abnormal findings in physical examination, vital signs, ECG, laboratory tests could affect patient safety, study findings or the patient's ability to complete the study.
- Cor pulmonale and/or right ventricular failure.
- Long-term treatment with oxygen \>4.0 L/min and/or oxyhemoglobin saturation \<89% while breathing supplemental oxygen.
- Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of CPAP for Sleep Apnea Syndrome is allowed.
- Known immunodeficiency disorder, including positive HIV-1/2 testing.
- Active liver disease. Chronic stable hepatitis B and C (including positive HBsAg or hepatitis C antibody testing), or other stable chronic liver disease are acceptable.
- ALT or AST ≥3 times the upper limit of normal, confirmed by repeated testing during the run-in period.
- Helminth parasitic infection within 24 weeks prior to enrollment, not treated or failed to respond to standard of care therapy.
- Alcohol or drug abuse within the past year, which may compromise the study data.
- Malignancy, current or within the past 5 years, except for adequately treated non invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms.
- +13 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (343)
Research Site
Surprise, Arizona, 85374, United States
Research Site
Little Rock, Arkansas, 72209, United States
Research Site
Los Angeles, California, 90033, United States
Research Site
Los Angeles, California, 90048, United States
Research Site
Newport Beach, California, 92663, United States
Research Site
Northridge, California, 91324, United States
Research Site
Palm Springs, California, 92262, United States
Research Site
Westminster, California, 92683, United States
Research Site
Stamford, Connecticut, 06902, United States
Research Site
Clearwater, Florida, 33765, United States
Research Site
Daytona Beach, Florida, 32117, United States
Research Site
Edgewater, Florida, 32132, United States
Research Site
Jacksonville, Florida, 32204, United States
Research Site
Jacksonville, Florida, 32209, United States
Research Site
Kissimmee, Florida, 34741, United States
Research Site
Kissimmee, Florida, 34746, United States
Research Site
Leesburg, Florida, 34748, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Orlando, Florida, 32819, United States
Research Site
Pensacola, Florida, 32503, United States
Research Site
St. Petersburg, Florida, 33707, United States
Research Site
Tampa, Florida, 33607, United States
Research Site
Winter Park, Florida, 32789, United States
Research Site
Lawrenceville, Georgia, 30046, United States
Research Site
Rincon, Georgia, 31326, United States
Research Site
Chicago, Illinois, 60611, United States
Research Site
O'Fallon, Illinois, 62269, United States
Research Site
Peoria, Illinois, 61636, United States
Research Site
Michigan City, Indiana, 46360, United States
Research Site
Iowa City, Iowa, 52242, United States
Research Site
Kansas City, Kansas, 66160, United States
Research Site
Georgetown, Kentucky, 40324, United States
Research Site
Baltimore, Maryland, 21224, United States
Research Site
Columbia, Maryland, 21044, United States
Research Site
Boston, Massachusetts, 02215, United States
Research Site
North Dartmouth, Massachusetts, 02747, United States
Research Site
Farmington Hills, Michigan, 48336, United States
Research Site
Lincoln, Nebraska, 68510, United States
Research Site
Omaha, Nebraska, 68124, United States
Research Site
Toms River, New Jersey, 08755, United States
Research Site
Buffalo, New York, 14215, United States
Research Site
New Windsor, New York, 12553, United States
Research Site
The Bronx, New York, 10461, United States
Research Site
Burlington, North Carolina, 27215, United States
Research Site
Charlotte, North Carolina, 28277, United States
Research Site
Elizabeth City, North Carolina, 27909, United States
Research Site
Gastonia, North Carolina, 28054, United States
Research Site
Mooresville, North Carolina, 28117, United States
Research Site
New Bern, North Carolina, 28562, United States
Research Site
Wilmington, North Carolina, 28401, United States
Research Site
Winston-Salem, North Carolina, 27103, United States
Research Site
Cleveland, Ohio, 44106, United States
Research Site
Columbus, Ohio, 43215, United States
Research Site
Oklahoma City, Oklahoma, 73106, United States
Research Site
Medford, Oregon, 97504, United States
Research Site
DuBois, Pennsylvania, 15801, United States
Research Site
Philadelphia, Pennsylvania, 19140, United States
Research Site
Pittsburgh, Pennsylvania, 15213, United States
Research Site
Smithfield, Pennsylvania, 15478, United States
Research Site
Mt. Pleasant, South Carolina, 29464, United States
Research Site
North Charleston, South Carolina, 29406, United States
Research Site
Rock Hill, South Carolina, 29732, United States
Research Site
Rapid City, South Dakota, 57702, United States
Research Site
Chattanooga, Tennessee, 37404, United States
Research Site
Franklin, Tennessee, 37067, United States
Research Site
Hendersonville, Tennessee, 37075, United States
Research Site
Johnson City, Tennessee, 37601, United States
Research Site
Amarillo, Texas, 79106, United States
Research Site
Amarillo, Texas, 79124, United States
Research Site
Cypress, Texas, 77429, United States
Research Site
Dallas, Texas, 75390, United States
Research Site
Fort Worth, Texas, 76104, United States
Research Site
Houston, Texas, 77079, United States
Research Site
Kerrville, Texas, 78028, United States
Research Site
San Antonio, Texas, 78258, United States
Research Site
Tomball, Texas, 77375, United States
Research Site
Salt Lake City, Utah, 84102, United States
Research Site
Abingdon, Virginia, 24210, United States
Research Site
Salem, Virginia, 24153, United States
Research Site
Williamsburg, Virginia, 23188, United States
Research Site
Everett, Washington, 98208, United States
Research Site
Spokane, Washington, 99204, United States
Research Site
Morgantown, West Virginia, 26505, United States
Research Site
Cudahy, Wisconsin, 53110, United States
Research Site
Buenos Aires, S2000PBJ, Argentina
Research Site
CABA, C1012AAR, Argentina
Research Site
Ciudad Autónoma de Buenos Aire, C1440BRR, Argentina
Research Site
Ciudad de Buenos Aires, 1425, Argentina
Research Site
Córdoba, X5003DCE, Argentina
Research Site
Florida, B1602DQD, Argentina
Research Site
Mar del Plata, B7600GWV, Argentina
Research Site
Mendoza, M5500CCG, Argentina
Research Site
San Fernando, B1646EBJ, Argentina
Research Site
San Juan Bautista, 1888, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
Caringbah, 2229, Australia
Research Site
Melbourne, 3004, Australia
Research Site
South Brisbane, 4101, Australia
Research Site
Southport, 4215, Australia
Research Site
Spearwood, 6163, Australia
Research Site
Bad Ischl, 4820, Austria
Research Site
Bludenz, 6700, Austria
Research Site
Feldbach, A-8330, Austria
Research Site
Grieskirchen, 4710, Austria
Research Site
Linz, 4020, Austria
Research Site
Thalheim, 4600, Austria
Research Site
Edegem, 2650, Belgium
Research Site
Erpent, 5101, Belgium
Research Site
Blumenau, 89030-101, Brazil
Research Site
Botucatu, 18.618-686, Brazil
Research Site
Florianópolis, 88036-800, Brazil
Research Site
Maringá, 87015-000, Brazil
Research Site
Porto Alegre, 9002-060, Brazil
Research Site
Porto Alegre, 90020-090, Brazil
Research Site
Porto Alegre, 90610-000, Brazil
Research Site
Porto Alegre, 91350-200, Brazil
Research Site
Santo André, 09080-110, Brazil
Research Site
São Bernardo do Campo, 09750-420, Brazil
Research Site
São Paulo, 05403-000, Brazil
Research Site
Sorocaba, 18040-425, Brazil
Research Site
Kozloduy, 3320, Bulgaria
Research Site
Rousse, 7002, Bulgaria
Research Site
Stara Zagora, 6003, Bulgaria
Research Site
Calgary, Alberta, T3B 0M3, Canada
Research Site
St. John's, NF, A1A 3R5, Canada
Research Site
Ajax, Ontario, L1S 2J5, Canada
Research Site
Barrie, Ontario, L4M 6M2, Canada
Research Site
Sarnia, Ontario, N7T 4X3, Canada
Research Site
Stouffville, Ontario, L4A 1H2, Canada
Research Site
Toronto, Ontario, M5T 3A9, Canada
Research Site
Toronto, Ontario, M9V 4B4, Canada
Research Site
Montreal, Quebec, H4A 3J1, Canada
Research Site
Québec, Quebec, G1V 4W2, Canada
Research Site
Québec, Quebec, G1W 4R4, Canada
Research Site
Québec, Quebec, G2J 0C4, Canada
Research Site
Saskatoon, Saskatchewan, S7N 0W8, Canada
Research Site
Chicoutimi, G7H 5H6, Canada
Research Site
Chile, 7770484, Chile
Research Site
Curicó, 3341643, Chile
Research Site
Quillota, 2260000, Chile
Research Site
Santiago, 7500571, Chile
Research Site
Santiago, 7500698, Chile
Research Site
Santiago, 8380453, Chile
Research Site
Talca, 3465584, Chile
Research Site
Baotou, 14010, China
Research Site
Beijing, 100034, China
Research Site
Beijing, 102218, China
Research Site
Changsha, 410005, China
Research Site
Changsha, 410015, China
Research Site
Changsha, 430033, China
Research Site
Chengdu, 610041, China
Research Site
Chongqing, 402260, China
Research Site
Ganzhou, 341099, China
Research Site
Guangzhou, 510180, China
Research Site
Guiyang, 550002, China
Research Site
Haikou, 570311, China
Research Site
Hebei, China
Research Site
Hefei, 230001, China
Research Site
Hohhot, 010017, China
Research Site
Hohhot, 10050, China
Research Site
Linhai, 317000, China
Research Site
Nanchang, 330006, China
Research Site
Shanghai, 200002, China
Research Site
Shanghai, 200032, China
Research Site
Shanghai, 200433, China
Research Site
Shenzhen, 518020, China
Research Site
Suzhou, 215000, China
Research Site
Ürümqi, 830054, China
Research Site
Wenzhou, 325027, China
Research Site
Wuhan, 430022, China
Research Site
Wuhan, 430030, China
Research Site
Xi'an, 710061, China
Research Site
Yinchuan, 750001, China
Research Site
Zhanjiang, 524001, China
Research Site
Zhengzhou, 450003, China
Research Site
Barranquilla, 80007, Colombia
Research Site
Cali, 76001000, Colombia
Research Site
Floridablanca, 681004, Colombia
Research Site
Medellín, 5001000, Colombia
Research Site
Pereira, 660003, Colombia
Research Site
Zipaquirá, 200251, Colombia
Research Site
Brandýs nad Labem, 250 01, Czechia
Research Site
Jindřichův Hradec, 377 01, Czechia
Research Site
Ostrava, 708 68, Czechia
Research Site
Rokycany, 337 22, Czechia
Research Site
Teplice, 415 01, Czechia
Research Site
Aalborg, 9000, Denmark
Research Site
Hvidovre, 2650, Denmark
Research Site
København NV, 2400, Denmark
Research Site
Odense C, 5000, Denmark
Research Site
Roskilde, 4000, Denmark
Research Site
Vejle, 7100, Denmark
Research Site
Bamberg, 96049, Germany
Research Site
Berlin, 10717, Germany
Research Site
Berlin, 12157, Germany
Research Site
Berlin, 13187, Germany
Research Site
Cologne, 51069, Germany
Research Site
Darmstadt, 64283, Germany
Research Site
Hamburg, 20354, Germany
Research Site
Hanover, D-30173, Germany
Research Site
Koblenz, 56068, Germany
Research Site
Leipzig, 04103, Germany
Research Site
Leipzig, 04207, Germany
Research Site
Leipzig, 04357, Germany
Research Site
Marburg, 35037, Germany
Research Site
Neu-Isenburg, 63263, Germany
Research Site
Peine, 31224, Germany
Research Site
Potsdam, 14467, Germany
Research Site
Rheine, 48431, Germany
Research Site
Warendorf, 48231, Germany
Research Site
Athens, 11527, Greece
Research Site
Exohi Thessaloniki, 57010, Greece
Research Site
Ioannina, 45500, Greece
Research Site
Thessaloniki, 56429, Greece
Research Site
Thessaloniki, 57010, Greece
Research Site
Balassagyarmat, 2660, Hungary
Research Site
Budapest, 1033, Hungary
Research Site
Edelény, 3780, Hungary
Research Site
Encs, 3860, Hungary
Research Site
Gödöllő, 2100, Hungary
Research Site
Hajdúnánás, 4080, Hungary
Research Site
Komárom, 2900, Hungary
Research Site
Pécs, 7635, Hungary
Research Site
Siófok, 8600, Hungary
Research Site
Százhalombatta, 2440, Hungary
Research Site
Szeged, 6722, Hungary
Research Site
Törökbálint, 2045, Hungary
Research Site
Calicut, 673 008, India
Research Site
Coimbatore, 641028, India
Research Site
Guntur, 522001, India
Research Site
Hyderabad, 500038, India
Research Site
Jaipur, 302039, India
Research Site
Thane, 401107, India
Research Site
Vijayawada, 520 008, India
Research Site
Cona, 44124, Italy
Research Site
Genoa, 16132, Italy
Research Site
Milan, 20142, Italy
Research Site
Milan, 20157, Italy
Research Site
Napoli, 80131, Italy
Research Site
Reggio Emilia, 42123, Italy
Research Site
Roma, 00168, Italy
Research Site
Rozzano, 20089, Italy
Research Site
Chūōku, 103-0022, Japan
Research Site
Chūōku, 104-0031, Japan
Research Site
Fukuoka, 814-0180, Japan
Research Site
Himeji-shi, 672-8064, Japan
Research Site
Hitachi-Naka, 312-0057, Japan
Research Site
Joyo-shi, 610-0113, Japan
Research Site
Kawachinagano-shi, 586-8521, Japan
Research Site
Kishiwada-shi, 596-8501, Japan
Research Site
Kobe, 650-0047, Japan
Research Site
Kōtoku, 136-0075, Japan
Research Site
Kure-shi, 737-0023, Japan
Research Site
Matsusaka-shi, 515-8544, Japan
Research Site
Mizunami-shi, 509-6134, Japan
Research Site
Nagaoka-shi, 940-2085, Japan
Research Site
Nagoya, 457-8511, Japan
Research Site
Nishinomiya-shi, 663-8501, Japan
Research Site
Okayama, 700-8558, Japan
Research Site
Osaka, 531-0073, Japan
Research Site
Sagamihara-shi, 252-0315, Japan
Research Site
Sakaide-shi, 762-8550, Japan
Research Site
Sakaishi, 591-8555, Japan
Research Site
Seto-shi, 489-8642, Japan
Research Site
Shinagawa-ku, 140-8522, Japan
Research Site
Shinagawa-ku, 142-8666, Japan
Research Site
Toshima-ku, 170-0002, Japan
Research Site
Toshima-ku, 170-0003, Japan
Research Site
Toshima-ku, 171-0014, Japan
Research Site
Toyonaka-shi, 560-8552, Japan
Research Site
Ueda-shi, 386-8610, Japan
Research Site
Yanagawa-shi, 832-0059, Japan
Research Site
Yokohama, 223-0059, Japan
Research Site
Guadalajara, 44100, Mexico
Research Site
Guadalajara, 44130, Mexico
Research Site
Guadalajara, 44200, Mexico
Research Site
Mérida, 97070, Mexico
Research Site
Veracruz, 91910, Mexico
Research Site
Breda, 4818 CK, Netherlands
Research Site
Leeuwarden, 8934 AD, Netherlands
Research Site
Auckland, 0626, New Zealand
Research Site
Auckland, 1051, New Zealand
Research Site
Christchurch, 8024, New Zealand
Research Site
Dunedin, 9016, New Zealand
Research Site
Hamilton, 3204, New Zealand
Research Site
Iloilo City, 5000, Philippines
Research Site
Los Baños, 4030, Philippines
Research Site
Marilao, 3019, Philippines
Research Site
Quezon City, 1100, Philippines
Research Site
Bialystok, 15-044, Poland
Research Site
Chęciny, 26-060, Poland
Research Site
Grodzisk Mazowiecki, 05-825, Poland
Research Site
Katowice, 40-648, Poland
Research Site
Lodz, 90-153, Poland
Research Site
Ostrowiec Świętokrzyski, 27-400, Poland
Research Site
Poznan, 60-693, Poland
Research Site
Poznan, 61-578, Poland
Research Site
Proszowice, 32-100, Poland
Research Site
Rzeszów, 35-051, Poland
Research Site
Warsaw, 02-793, Poland
Research Site
Wieluń, 98-300, Poland
Research Site
Daegu, 42415, South Korea
Research Site
Jeonju, 54907, South Korea
Research Site
Seoul, 03312, South Korea
Research Site
Seoul, 04401, South Korea
Research Site
Seoul, 05030, South Korea
Research Site
Seoul, 06591, South Korea
Research Site
Wŏnju, 26426, South Korea
Research Site
Barcelona, 08017, Spain
Research Site
Hospitalet de Llobregat(Barcel, 08907, Spain
Research Site
Laredo, 39770, Spain
Research Site
Madrid, 28007, Spain
Research Site
Madrid, 28046, Spain
Research Site
Madrid, 28850, Spain
Research Site
Málaga, 29010, Spain
Research Site
Santander, 39008, Spain
Research Site
Gothenburg, 413 46, Sweden
Research Site
Göteborg, 413 45, Sweden
Research Site
Lund, 222 22, Sweden
Research Site
Malmo, 205 02, Sweden
Research Site
Stockholm, 114 46, Sweden
Research Site
Adana, 01330, Turkey (Türkiye)
Research Site
Istanbul, 34098, Turkey (Türkiye)
Research Site
Istanbul, 34844, Turkey (Türkiye)
Research Site
Izmir, 35110, Turkey (Türkiye)
Research Site
Kocaeli, 41380, Turkey (Türkiye)
Research Site
Mersin, 33343, Turkey (Türkiye)
Research Site
Barnsley, S75 3DL, United Kingdom
Research Site
Birmingham, B9 5SS, United Kingdom
Research Site
Blackpool, FY2 0JH, United Kingdom
Research Site
Bradford, BD9 6RJ, United Kingdom
Research Site
Chertsey, KT16 0PZ, United Kingdom
Research Site
Cottingham, HU16 5JQ, United Kingdom
Research Site
Leicester, LE3 9QP, United Kingdom
Research Site
Manchester, M13 9NQ, United Kingdom
Research Site
Oxford, OX3 7LE, United Kingdom
Research Site
Perth, PH1 1NX, United Kingdom
Research Site
Southampton, SO166YD, United Kingdom
Research Site
Stockton-on-Tees, TS17 6EW, United Kingdom
Research Site
Wishaw, ML2 0DP, United Kingdom
Research Site
Hanoi, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Hồ Chí Minh, 700000, Vietnam
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gerard Criner, MD
Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 16, 2019
First Posted
August 12, 2019
Study Start
August 26, 2019
Primary Completion
July 28, 2025
Study Completion
July 28, 2025
Last Updated
August 19, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment.